LETERMOVIR FOR CYTOMEGALOVIRUS PROPHYLAXIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE RESULTS OF LETREAL STUDY. (EHA 2026) - May 12, 2026 - Abstract #EHA-6559; PS2216; Pres time: Jun 13, 2026; 06:45 PM - 07:45 PM; Location: Hall A; "The comparison of cs-CMV infection at 100 days after allo-HSCT after PSM adjusted. Allo-HSCT, allogeneic hematopoietic stem cell transplantation; TBI, total body irradiation; MSD, matched sibling donor; HID, haploidentical related donor; MUD, matched unrelated donor; GVHD, graft-versus-host disease; ATG, antithymocyte globulin; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HR, hazard ratio; 95% CI, 95% confidence interval."
Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia
|
|
Yi Xia 1; Qi Wen 1; Jinfang Zhao 1; Xiaohui Zhang 1; Lanping Xu 1; Yu Wang 1; Chen-Hua Yan 1; Yu-Hong Chen 1; Wei Han 1; Feng- Rong Wang 1; Jing-Zhi Wang 1; Jun Kong 1; Tingting Han 1; Leqing Cao 1; Dao-Xing Deng 1; Xiao-Dong Mo1
|